Free tool
FAERS Monitor: Procysbi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213491 or its brand name (Procysbi, Cysteamine Bitartrate). Reports on generic versions are filed under their own applications.
Reports
758
Serious
403
53% of reports
Hospitalization
226
Death reported
38
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- vomiting113
- nausea104
- eye irritation47
- abdominal pain upper32
- diarrhoea32
- abdominal discomfort30
- malaise28
- death25
- headache25
- product dose omission issue23
- illness22
- amino acid level increased21
- renal transplant21
- pneumonia18
- fatigue17
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 2 |
| 2014 | 15 |
| 2016 | 3 |
| 2017 | 25 |
| 2018 | 93 |
| 2019 | 102 |
| 2020 | 116 |
| 2021 | 78 |
| 2022 | 38 |
| 2023 | 57 |
| 2024 | 130 |
| 2025 | 60 |
| 2026 | 39 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,401 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| amino acid level increasedSignal | 21 | 807.9 | 526.6 | 15,671 |
| renal transplantSignal | 21 | 162.2 | 106.3 | 3,188 |
| eye irritationSignal | 47 | 22.7 | 17.2 | 954 |
| vomitingSignal | 113 | 6.7 | 5.6 | 551 |
| illnessSignal | 22 | 5.9 | 3.9 | 86 |
| abdominal discomfortSignal | 30 | 5.0 | 3.5 | 92 |
| abdominal pain upperSignal | 32 | 4.3 | 3.1 | 79 |
| nauseaSignal | 104 | 3.6 | 3.1 | 205 |
| product dose omission issueSignal | 23 | 2.2 | 1.5 | 14 |
| malaise | 28 | 1.8 | 1.2 | 9 |
| pneumonia | 18 | 1.5 | 1.0 | 3 |
| diarrhoea | 32 | 1.4 | 1.0 | 3 |
| headache | 25 | 1.1 | 0.8 | 0 |
| death | 25 | 0.8 | 0.5 | 1 |
| fatigue | 17 | 0.6 | 0.4 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.